ImmuneOnco doses first patient in Instil's IMM2510 Phase 1b/2 NSCLC trial; data in 2H 2025

Instil Bio, Inc.

ImmuneOnco dosed first patient in combined-chemotherapy trial for advanced NSCLC in China.
Initial clinical data for 1L advanced NSCLC expected as early as second half of 2025.
Instil targets initiating U.S. first-line NSCLC trial of IMM2510 plus chemo in 2H 2025, subject to regulatory approvals.
CEO Bronson Crouch says positive data could enable a global registrational study in front-line NSCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.